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LETTERS TO THE EDITOR
Parathyroidectomy in ESRD
To the Editor: Kestenbaum et al have confirmed that
parathyroidectomy rates in the United States have fallen
since 1990, and, in an accompanying editorial, a plea
is made for improved management of secondary hyper-
parathyroidism [1, 2]. We agree completely that use of
parathyroidectomy has declined in the United States, and
we reported this in 2001 [3]. Similar findings were re-
ported from Japan [4].
But use of parathyroidectomy rates is an imperfect
yardstick of the management of secondary hyperparathy-
roidism. Use of parathyroidectomy is a low-frequency oc-
currence, affecting less than one dialysis patient per 100
per year. It is possible that there is a small but inerad-
icable fraction of end-stage renal disease (ESRD) pa-
tients who will respond poorly to medical management of
secondary hyperparathyroidism, and will thus ultimately
require what amounts to parathyroid debulking. Just be-
cause parathyroidectomies are still needed in 2003 does
not mean that we are doing a bad job with our current
management of secondary hyperparathyroidism. Recent
data suggest that the time from first ESRD to parathy-
roidectomy has lengthened significantly over the past
decade, and is now a median of six years [abstract; Co-
hen EP, J Am Soc Nephrol 14:684a, 2003]. It is possi-
ble that indications for parathyroidectomy have gradually
and linearly changed over this time. But that seems un-
likely. Thus, current medical management—better dialy-
sis, better phosphate binders, use of vitamin D analogs—
appears to have had an impact. Use of this surgery, and
time-to-need-for-surgery, has evolved in a favorable di-
rection. New agents, such as calcimimetics, may improve
more subtle aspects of secondary hyperparathyroidism,
but may not materially affect parathyroidectomy rates.
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Reply from the Authors
Cohen and Moulder [1] have previously reported a
decline in the prevalence of parathyroidectomy (PTX)
in the United States. Our study examined the adjusted
PTX incidence rate, accounting for changes in character-
istics of the dialysis population. During the years 1990 to
1999, there were significant increases in age, and in the
proportion of diabetic patients, among the U.S. ESRD
population. Because increasing age and diabetes suppress
parathyroid hormone levels, and likely result in a patient
population that is less fit for elective surgery, our con-
cern was that PTX rates might be declining as a result of
changes in patient characteristics. Our analyses showed
that changes in patient characteristics accounted for only
part of the decline in PTX rates, the remainder of the
decline being presumably from changes in patient care.
Of note, there was also some suggestion that the rate of
PTX has begun to increase again. This, in conjunction
with the data from Cohen et al, suggests that improved
management of hyperparathyroidism (HPT) with better
phosphate binders and the use of vitamin D analogs may
have simply altered the rate of progression of disease.
We agree that PTX rates provide only a composite of
the degree of control of hyperparathyroidism because it
represents only those persons with the most severe dis-
ease. It is quite possible that we have made significant im-
provements in care for those with more moderate HPT.
Further, it is unclear whether reduction in the PTX rate
is a positive or negative outcome. If disease management
has not been improved, but PTX is occurring less fre-
quently, patient outcomes may be worse. However, given
the lack of available data comparing patient outcomes
after PTX to those of similar patients not undergoing
surgery, conclusions are difficult to make.
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